CD8A and neoplasm: When combined with anti-PD-L1, doxil therapy enhanced the percentage of CD8+T cells that infiltrated tumors while decreasing the percentage of regulatory T cells Doxil treatment boosted mature dendritic cells’ expression of CD80 in the tumor indicating that Doxil may cause these tumor-infiltrating cells to develop a costimulatory phenotype that can stimulate an anticancer T-cell response.